Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IL4R_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IL4R_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IL4R_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IL4R_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/IL4R_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004561912 | Oral cavity | EOLP | regulation of lymphocyte differentiation | 40/2218 | 174/18723 | 2.54e-05 | 3.75e-04 | 40 |
GO:00511467 | Oral cavity | EOLP | striated muscle cell differentiation | 57/2218 | 283/18723 | 3.82e-05 | 5.25e-04 | 57 |
GO:002240918 | Oral cavity | EOLP | positive regulation of cell-cell adhesion | 57/2218 | 284/18723 | 4.23e-05 | 5.77e-04 | 57 |
GO:002240812 | Oral cavity | EOLP | negative regulation of cell-cell adhesion | 43/2218 | 196/18723 | 4.26e-05 | 5.79e-04 | 43 |
GO:005165623 | Oral cavity | EOLP | establishment of organelle localization | 73/2218 | 390/18723 | 4.59e-05 | 6.11e-04 | 73 |
GO:00022633 | Oral cavity | EOLP | cell activation involved in immune response | 56/2218 | 279/18723 | 4.91e-05 | 6.47e-04 | 56 |
GO:00023662 | Oral cavity | EOLP | leukocyte activation involved in immune response | 55/2218 | 275/18723 | 6.32e-05 | 7.90e-04 | 55 |
GO:00512503 | Oral cavity | EOLP | negative regulation of lymphocyte activation | 36/2218 | 157/18723 | 6.66e-05 | 8.27e-04 | 36 |
GO:00022852 | Oral cavity | EOLP | lymphocyte activation involved in immune response | 42/2218 | 194/18723 | 7.17e-05 | 8.82e-04 | 42 |
GO:0046637 | Oral cavity | EOLP | regulation of alpha-beta T cell differentiation | 20/2218 | 68/18723 | 7.88e-05 | 9.51e-04 | 20 |
GO:19030382 | Oral cavity | EOLP | negative regulation of leukocyte cell-cell adhesion | 33/2218 | 141/18723 | 8.63e-05 | 1.02e-03 | 33 |
GO:00508663 | Oral cavity | EOLP | negative regulation of cell activation | 44/2218 | 210/18723 | 1.09e-04 | 1.23e-03 | 44 |
GO:0043370 | Oral cavity | EOLP | regulation of CD4-positive, alpha-beta T cell differentiation | 16/2218 | 51/18723 | 1.75e-04 | 1.80e-03 | 16 |
GO:00455803 | Oral cavity | EOLP | regulation of T cell differentiation | 33/2218 | 146/18723 | 1.75e-04 | 1.81e-03 | 33 |
GO:19037075 | Oral cavity | EOLP | negative regulation of hemopoiesis | 26/2218 | 106/18723 | 2.11e-04 | 2.11e-03 | 26 |
GO:19021065 | Oral cavity | EOLP | negative regulation of leukocyte differentiation | 25/2218 | 102/18723 | 2.80e-04 | 2.69e-03 | 25 |
GO:00026953 | Oral cavity | EOLP | negative regulation of leukocyte activation | 39/2218 | 187/18723 | 2.89e-04 | 2.74e-03 | 39 |
GO:190210713 | Oral cavity | EOLP | positive regulation of leukocyte differentiation | 34/2218 | 157/18723 | 3.32e-04 | 3.08e-03 | 34 |
GO:190370813 | Oral cavity | EOLP | positive regulation of hemopoiesis | 34/2218 | 157/18723 | 3.32e-04 | 3.08e-03 | 34 |
GO:00028193 | Oral cavity | EOLP | regulation of adaptive immune response | 38/2218 | 183/18723 | 3.75e-04 | 3.40e-03 | 38 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04151 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
hsa041511 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
hsa046599 | Esophagus | ESCC | Th17 cell differentiation | 68/4205 | 108/8465 | 3.53e-03 | 9.30e-03 | 4.76e-03 | 68 |
hsa046585 | Esophagus | ESCC | Th1 and Th2 cell differentiation | 58/4205 | 92/8465 | 6.49e-03 | 1.60e-02 | 8.19e-03 | 58 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0465914 | Esophagus | ESCC | Th17 cell differentiation | 68/4205 | 108/8465 | 3.53e-03 | 9.30e-03 | 4.76e-03 | 68 |
hsa0465812 | Esophagus | ESCC | Th1 and Th2 cell differentiation | 58/4205 | 92/8465 | 6.49e-03 | 1.60e-02 | 8.19e-03 | 58 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa046598 | Oral cavity | OSCC | Th17 cell differentiation | 65/3704 | 108/8465 | 4.02e-04 | 1.25e-03 | 6.35e-04 | 65 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa046584 | Oral cavity | OSCC | Th1 and Th2 cell differentiation | 53/3704 | 92/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 53 |
hsa0465913 | Oral cavity | OSCC | Th17 cell differentiation | 65/3704 | 108/8465 | 4.02e-04 | 1.25e-03 | 6.35e-04 | 65 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0465811 | Oral cavity | OSCC | Th1 and Th2 cell differentiation | 53/3704 | 92/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 53 |
hsa0465923 | Oral cavity | EOLP | Th17 cell differentiation | 41/1218 | 108/8465 | 9.84e-10 | 3.18e-08 | 1.87e-08 | 41 |
hsa0465821 | Oral cavity | EOLP | Th1 and Th2 cell differentiation | 31/1218 | 92/8465 | 2.27e-06 | 1.79e-05 | 1.05e-05 | 31 |
hsa053214 | Oral cavity | EOLP | Inflammatory bowel disease | 20/1218 | 65/8465 | 5.49e-04 | 2.16e-03 | 1.28e-03 | 20 |
hsa0415123 | Oral cavity | EOLP | PI3K-Akt signaling pathway | 73/1218 | 354/8465 | 7.03e-04 | 2.69e-03 | 1.59e-03 | 73 |
hsa04630 | Oral cavity | EOLP | JAK-STAT signaling pathway | 35/1218 | 166/8465 | 1.15e-02 | 3.07e-02 | 1.81e-02 | 35 |
hsa0465933 | Oral cavity | EOLP | Th17 cell differentiation | 41/1218 | 108/8465 | 9.84e-10 | 3.18e-08 | 1.87e-08 | 41 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IL4R | SNV | Missense_Mutation | | c.971C>A | p.Pro324His | p.P324H | P24394 | protein_coding | tolerated(0.21) | benign(0.187) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
IL4R | SNV | Missense_Mutation | novel | c.352A>C | p.Ser118Arg | p.S118R | P24394 | protein_coding | deleterious(0.04) | probably_damaging(0.993) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IL4R | SNV | Missense_Mutation | novel | c.353G>C | p.Ser118Thr | p.S118T | P24394 | protein_coding | deleterious(0.04) | possibly_damaging(0.578) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IL4R | SNV | Missense_Mutation | | c.293N>T | p.Asn98Ile | p.N98I | P24394 | protein_coding | tolerated(0.29) | benign(0.003) | TCGA-A8-A091-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD |
IL4R | SNV | Missense_Mutation | | c.761N>A | p.Ser254Asn | p.S254N | P24394 | protein_coding | deleterious(0.02) | possibly_damaging(0.462) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IL4R | SNV | Missense_Mutation | novel | c.2143N>C | p.Ala715Pro | p.A715P | P24394 | protein_coding | deleterious(0.01) | probably_damaging(0.946) | TCGA-AO-A1KT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
IL4R | SNV | Missense_Mutation | | c.2462A>G | p.Tyr821Cys | p.Y821C | P24394 | protein_coding | tolerated(0.37) | benign(0) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
IL4R | SNV | Missense_Mutation | novel | c.1805N>C | p.Gly602Ala | p.G602A | P24394 | protein_coding | tolerated(0.05) | benign(0.07) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
IL4R | SNV | Missense_Mutation | | c.731T>A | p.Ile244Asn | p.I244N | P24394 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IL4R | SNV | Missense_Mutation | | c.2260N>T | p.Pro754Ser | p.P754S | P24394 | protein_coding | tolerated(0.32) | benign(0.211) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3566 | IL4R | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Hepatitis vaccines | | 21111021 |
3566 | IL4R | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | PRX-321 | PRX-321 | |
3566 | IL4R | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | CHEMBL2108583 | CINTREDEKIN BESUDOTOX | |
3566 | IL4R | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | AIR645 | | |
3566 | IL4R | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | SAR-156597 | ROMILKIMAB | |
3566 | IL4R | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | Aerovant | | |
3566 | IL4R | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | CINTREDEKIN BESUDOTOX | | |
3566 | IL4R | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | AER001,AEROVANT | | |
3566 | IL4R | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | antibody | 223365910 | DUPILUMAB | |
3566 | IL4R | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | pitrakinra | PITRAKINRA | |